3.55 USD
-0.36 (-9.21%)
At close: Jan 30, 2026
3.62 USD
+0.07 (+1.97%)
After Hours: 1/30/2026, 8:17:07 PM
RLMD gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 191 industry peers in the Pharmaceuticals industry. RLMD scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. RLMD is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
- In the past year RLMD has reported negative net income.
- RLMD had a negative operating cash flow in the past year.
- RLMD had negative earnings in each of the past 5 years.
- In the past 5 years RLMD always reported negative operating cash flow.
1.2 Ratios
- With a Return On Assets value of -377.61%, RLMD is not doing good in the industry: 94.76% of the companies in the same industry are doing better.
- RLMD's Return On Equity of -593.47% is on the low side compared to the rest of the industry. RLMD is outperformed by 81.68% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -377.61% | ||
| ROE | -593.47% | ||
| ROIC | N/A |
ROA(3y)-126.18%
ROA(5y)-97.03%
ROE(3y)-150.91%
ROE(5y)-113.88%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- RLMD does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- RLMD has more shares outstanding than it did 1 year ago.
- The number of shares outstanding for RLMD has been increased compared to 5 years ago.
- There is no outstanding debt for RLMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- Based on the Altman-Z score of -47.03, we must say that RLMD is in the distress zone and has some risk of bankruptcy.
- RLMD has a Altman-Z score of -47.03. This is amonst the worse of the industry: RLMD underperforms 92.15% of its industry peers.
- There is no outstanding debt for RLMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -47.03 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
- RLMD has a Current Ratio of 2.86. This indicates that RLMD is financially healthy and has no problem in meeting its short term obligations.
- RLMD has a Current ratio of 2.86. This is comparable to the rest of the industry: RLMD outperforms 49.74% of its industry peers.
- RLMD has a Quick Ratio of 2.86. This indicates that RLMD is financially healthy and has no problem in meeting its short term obligations.
- RLMD has a Quick ratio of 2.86. This is comparable to the rest of the industry: RLMD outperforms 53.93% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.86 | ||
| Quick Ratio | 2.86 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 37.28% over the past year.
EPS 1Y (TTM)37.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%58.33%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
- RLMD is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 9.59% yearly.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y54.97%
EPS Next 2Y32.28%
EPS Next 3Y20.1%
EPS Next 5Y9.59%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
- RLMD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RLMD. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A more expensive valuation may be justified as RLMD's earnings are expected to grow with 20.10% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.28%
EPS Next 3Y20.1%
5. Dividend
5.1 Amount
- No dividends for RLMD!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
RELMADA THERAPEUTICS INC / RLMD FAQ
What is the fundamental rating for RLMD stock?
ChartMill assigns a fundamental rating of 2 / 10 to RLMD.
What is the valuation status for RLMD stock?
ChartMill assigns a valuation rating of 1 / 10 to RELMADA THERAPEUTICS INC (RLMD). This can be considered as Overvalued.
How profitable is RELMADA THERAPEUTICS INC (RLMD) stock?
RELMADA THERAPEUTICS INC (RLMD) has a profitability rating of 0 / 10.
What is the financial health of RELMADA THERAPEUTICS INC (RLMD) stock?
The financial health rating of RELMADA THERAPEUTICS INC (RLMD) is 6 / 10.
What is the earnings growth outlook for RELMADA THERAPEUTICS INC?
The Earnings per Share (EPS) of RELMADA THERAPEUTICS INC (RLMD) is expected to grow by 54.97% in the next year.